Peles, Ido
Asla, Mohnnad
Abayev, Mariya
Gordon, Michal
Novack, Victor
Ribalov, Rinat
Lengil, Tamar
Maor, Ron
Elizur, Mayera
Ifergane, Gal
Funding for this research was provided by:
Teva Pharmaceuticals
Article History
Received: 7 June 2022
Accepted: 27 October 2022
First Online: 14 December 2022
Declarations
:
: The study was approved by the SUMC ethics committee, reference number 0284-19. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. The ethics committee approval exempted the study from informed consent due to the retrospective data collection that maintained subject confidentiality. Informed consent was waived by the institutional review board at SUMC. Patient records were anonymized and deidentified prior to analysis.
: Not applicable.
: I.P., M.As., M.Ab., M.G., V.N., and G.I. performed this research, funded by Teva Pharmaceuticals. R.R., T.L., R.M., and M.E. are employees of Teva Pharmaceuticals.